Oslo, Norway, May 11, 2023 - The Annual General Meeting of Nykode Therapeutics
ASA was held May 11, 2023. All proposed resolutions on the agenda were approved
in accordance with the notice for the meeting published on April 20, 2023.
Minutes of the meeting are attached hereto.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode's modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which have been shown to induce
broad, strong and long-lasting antigen specific immune responses which
correlates with clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive safety and efficacy results from its Phase 2 trial for the
treatment of cervical cancer